We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$7.99B
AUM Growth
+$1.36B
Cap. Flow
+$167M
Cap. Flow %
2.09%
Top 10 Hldgs %
82.62%
Holding
149
New
30
Increased
33
Reduced
21
Closed
40

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$40.6M
2
TSRO
TESARO, Inc.
TSRO
+$32.2M
3
BPMC
Blueprint Medicines
BPMC
+$30.2M
4
NKTR icon
Nektar Therapeutics
NKTR
+$25.8M
5
FOLD
Amicus Therapeutics
FOLD
+$22.8M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$21.1M
2
INCY icon
Incyte
INCY
+$18M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.37M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$5.83M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.72M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.57%
2 Consumer Discretionary 23.48%
3 Healthcare 17.53%
4 Communication Services 0.15%
5 Materials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FBRX icon
101
Forte Biosciences
FBRX
$1.57B
$1.19M 0.01%
267
– –
CRSP icon
102
CRISPR Therapeutics
CRSP
$4.69B
$1.14M 0.01%
25,000
-25,000
-50% -$1.03M
SLDB icon
103
Solid Biosciences
SLDB
$792M
$1.13M 0.01%
+10,000
New +$3.38M
TRIL
104
DELISTED
Trillium Therapeutics Inc.
TRIL
$1.08M 0.01%
150,000
– –
NVAX icon
105
Novavax
NVAX
$1.21B
$1.05M 0.01%
25,000
– –
NVLN
106
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$897K 0.01%
256,400
– –
EDIT icon
107
Editas Medicine
EDIT
$399M
$829K 0.01%
25,000
-25,000
-50% -$891K
XENE icon
108
Xenon Pharmaceuticals
XENE
$6.1B
$735K 0.01%
150,000
– –
IMDX
109
Insight Molecular Diagnostics
IMDX
$141M
$315K ﹤0.01%
7,500
– –
ADAP
110
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-700,000
Closed -$4.68M
ALNY icon
111
CALL
Alnylam Pharmaceuticals
ALNY
$38.3B
– –
-200,000
Closed -$25.4M
AMGN icon
112
CALL
Amgen
AMGN
$209B
– –
-100,000
Closed -$17.4M
BABA icon
113
CALL
Alibaba
BABA
$276B
– –
-200,000
Closed -$34.5M
BCRX icon
114
BioCryst Pharmaceuticals
BCRX
$2.42B
– –
-500,000
Closed -$2.46M
BHF icon
115
CALL
Brighthouse Financial
BHF
$3.61B
– –
-300,000
Closed -$17.6M
BLUE
116
CALL
DELISTED
bluebird bio
BLUE
– –
-3,860
Closed -$8.9M
C icon
117
CALL
Citigroup
C
$213B
– –
-1,500,000
Closed -$112M
CLDX icon
118
Celldex Therapeutics
CLDX
$2.94B
– –
-23,356
Closed -$995K
CLLS
119
Cellectis
CLLS
$288M
– –
-100,000
Closed -$2.92M
CRBP icon
120
Corbus Pharmaceuticals
CRBP
$165M
– –
-13,333
Closed -$2.84M
DVAX
121
DELISTED
Dynavax Technologies
DVAX
– –
-200,000
Closed -$3.45M
GILD icon
122
CALL
Gilead Sciences
GILD
$165B
– –
-1,250,000
Closed -$89.5M
HALO icon
123
Halozyme
HALO
$9.88B
– –
-150,000
Closed -$3.04M
IBRX icon
124
ImmunityBio
IBRX
$7.15B
– –
-225,000
Closed -$1.01M
LCTX icon
125
Lineage Cell Therapeutics
LCTX
$264M
– –
-1,779,708
Closed -$3.35M
2 3 4
5
6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2018 Portfolio in Review

As of Q1 2018, Artal Group held 149 positions worth $7.99B, up 21% from $6.63B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group's Q1 2018 filing shows 30 new, 33 increased, 21 reduced and 40 closed positions. Its largest new stake was Kyntra Bio: 10,000 shares worth $11.6M. The largest sale was Neurocrine Biosciences, an estimated $21.1M.

By sector, the portfolio is most concentrated in Consumer Staples at 44% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q1 2018 buy was Kyntra Bio: 10,000 shares worth $11.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q1 2018, an estimated $40.6M increase.
  • Artal Group's biggest Q1 2018 reduction was Incyte, cutting an estimated $18M.
  • Artal Group fully exited Neurocrine Biosciences in Q1 2018, selling an estimated $21.1M.
  • Artal Group's ten largest holdings make up 83% of its $7.99B portfolio in Q1 2018.
  • Artal Group opened 30 new positions and closed 40 in Q1 2018.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $7.99B.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.